Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

NexMed Announces Decision For Anti-Fungal Product
NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® technology, announced the mutual decision with Novartis to terminate the licensing agreement for NM100060, a topically-applied treatment for onychomycosis, commonly known as nail fungus. NexMed entered into the exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060.
generic viagra online
"Thousands Have Lived Without Love, Not One Without Water"
Water for Work and Home, an innovative wellbeing organisation, is providing the essential water to keep the "living monuments" hydrated whilst on the Fourth Plinth.
News of the day
White House Emphasizes Need To Reduce Health Care Costs, Improve Access To Care Among Blacks
During a White House teleconference last week, Nancy-Ann DeParle, director of the White House Office on Health Reform said that reducing health care costs is "particularly important for the [black] community because on average, they spend a higher percentage of their income on health care costs, compared to their white counterparts," the Washington Informer reports. Nancy-Ann DeParle, director of the office, at a press conference last week said that reducing health care costs is "particularly important for the [black] community because on average, they spend a higher percentage of their income on health care costs, compared to their white counterparts." She added that blacks spend about 16.5% of their income on health care, while whites spend about 12%. In addition, blacks "continue to face disparities in terms of the (quality of care) they get," DeParle said. According to DeParle, blacks tend to visit hospitals that "provide lower-quality care." She added that higher health care costs are "especially troubling" to the black community because blacks "suffer from higher percentages of chronic diseases such as heart disease, kidney disease and diabetes, that are due in part to a lack of access to quality care."According to the Informer, $1 billion of the $787 billion stimulus package that President Obama signed in February will be allocated to prevention efforts and public health campaigns (Michaels, Washington Informer, 5/21).
Oncology

Nile Therapeutics CD-NP Clinical Program For Acute Heart Failure Released From Clinical Hold By FDA

Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, received notification from the U.S. Food and Drug Administration (FDA) that the agency has released the Company"s CD-NP development program from clinical hold. As the next step, the Company will submit to the FDA the finalized protocol for the Company"s planned 30-patient single-blind, placebo-controlled Phase 2 study designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with acute heart failure and renal insufficiency. The dosing of the study is expected to be completed by the end of 2009. About CD-NP CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of acute heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. The Company believes that the current preclinical and clinical data supports the pharmacological hypothesis at doses that have been safely tolerated by patients, and provides CD-NP with the potential for favorable differentiation from other acute heart failure therapies. In addition to an initial indication for acute heart failure, CD-NP may have utility in other indications, which include preservation of cardiac function subsequent to acute myocardial infarction (AMI), and prevention of renal damage subsequent to cardiac surgery. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel, rationally designed natriuretic peptide. A key component of the company"s strategy is to acquire the global rights to additional compounds to expand its portfolio. Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile"s strategy, future operations, outlook, milestones, the timing and success of Nile"s product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile"s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile"s need to raise additional capital to fund its product development programs to completion, Nile"s reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission on March 12, 2009 and amended on April 23, 2009. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Nile Therapeutics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009